The novel coumarin[3,2-c]thiophene and its hydroxamic acid and ureido derivatives: synthesis and cytostatic activity evaluations
- 284 Downloads
In the present paper, we report on the synthesis and in vitro antitumour effects of novel hydroxamic acid (compounds 4 and 5) and ureido (compounds 7–11) derivatives containing coumarin[3,2-c]thiophene moiety. The results of antiproliferative assays performed on a panel of selected human tumour cell lines revealed stronger concentration-dependent antiproliferative activity of coumarin[3,2-c]thiophene (7–11) ureido derivatives in comparison with coumarin[3,2-c]thiophene hydroxamic acid derivatives (4 and 5). Nevertheless, compounds 7–10 were cytotoxic on normal human fibroblasts as well. Importantly, the ureido derivative 11 and hydroxamic acid derivatives 4 and 5 showed pronounced and selective inhibitory activity towards cervical carcinoma (HeLa) cell line with concomitant low or no cytotoxicity on normal human fibroblasts. These compounds can therefore be considered as potential antitumour lead compounds for further structural optimization.
KeywordsCoumarin[3,2-c]thiophene Urea Hydroxamic acid Antitumour
Support for this study was provided by the Ministry of Science, Education and Sports of the Republic of Croatia (Grant Nos. 125-0982464-2922, 335-0982464-239, 335-0000000-3532) and University of Rijeka research Grants 126.96.36.199.11 and 188.8.131.52.01.
- Avendano C, Menendez JC (2008) Medicinal chemistry of anticancer drugs. Elsevier, AmsterdamGoogle Scholar
- Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KBC, Harris CM, Hickman D, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Martin RL, Olson AM, Osterling DJ, Pease LJ, Soni NB, Stewart KD, Stoll VS, Tapang P, Reuter DR, Davidsen SK, Michaelides MR (2007) Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N’-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 50(7):1584–1597CrossRefPubMedGoogle Scholar
- Gazivoda T, Raić-Malić S, Kristafor V, Makuc D, Plavec J, Bratulić S, Kraljević-Pavelić S, Pavelić K, Naesens L, Andrei G, Snoeck R, Balzarini J, Mintas M (2008) Synthesis, cytostatic and anti-HIV evaluations of the new unsaturated acyclic C-5 pyrimidine nucleoside analogues. Bioorg Med Chem 16(10):5624–5634CrossRefPubMedGoogle Scholar
- Grese T, Pennington D, Sluka JP, Adrian MD, Cole HW, Fuson TR, Magee DE, Phillips DL, Rowley ER, Shetler PK, Short LL, Venugopalan M, Yang NN, Sato M, Glasebrook AL, Bryant HU (1998) Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J Med Chem 41(8):1272–1283CrossRefPubMedGoogle Scholar
- Janetka JW, Almeida L, Ashwell S, Brassil PJ, Daly K, Deng C, Gero T, Glynn RE, Horn CL, Ioannidis S, Lyne P, Newcombe NJ, Oza VB, Pass M, Springer SK, Su M, Toader D, Vasbinder MM, Yu D, Yu Y, Zabludoff SD (2008) Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. Bioorg Med Chem Lett 18(14):4242–4248CrossRefPubMedGoogle Scholar
- Jiang JD, Denner L, Ling YH, Li JN, Davis A, Wang Y, Li Y, Roboz JL, Wang LG, Roman PS, Marcelli M, Bekesi G, Holland JF (2002) Double blockade of cell cycle at G1-S transition and M phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand. Cancer Res 62:6080–6088PubMedGoogle Scholar
- Thaisrivongs S, Janakiraman MN, Chong KT, Tomich PK, Dolak LA, Turner SR, Strohbach JW, Lynn JC, Horng MM, Hinshaw RR, Watenpaugh KD (1996) Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors. J Med Chem 39(12):2400–2410CrossRefPubMedGoogle Scholar